Joan Korth-Bradley

Joan Korth-Bradley

Pfizer Inc. - New York / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4398216
-
person_outline Joan Korth-Bradley's MOST POPULAR ARTICLES
1-) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancerE Raymond, J Alexandre, S Faivre, K Vera, E Materman, J Boni, C Leister, ...Journal of clinical oncology 22 (12), 2336-2347, 20045572004
2-) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumoniaAT Freire, V Melnyk, MJ Kim, O Datsenko, O Dzyublik, F Glumcher, ...Diagnostic microbiology and infectious disease 68 (2), 140-151, 20103292010
3-) Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg doseKA Rodvold, MH Gotfried, M Cwik, JM Korth-Bradley, G Dukart, ...Journal of Antimicrobial Chemotherapy 58 (6), 1221-1229, 20063182006
4-) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumoniaJ Ramirez, N Dartois, H Gandjini, JL Yan, J Korth-Bradley, PC McGovernAntimicrobial agents and chemotherapy 57 (4), 1756-1762, 20133142013
5-) Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trialJ Alberú, MD Pascoe, JM Campistol, FP Schena, M del Carmen Rial, ...Transplantation 92 (3), 303-310, 20112592011